High serum miR-19a levels were associated with IBC, represented a prognostic biomarker for favorable clinical outcome in patients with metastatic HER2+ breast cancer and could be associated to an effective immune cell-mediated anti-tumor response. The gene discussed is ERBB2; the disease is neoplasm.